ANGELIQ

Angeliq Adverse Events Reported to the FDA Over Time

How are Angeliq adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Angeliq, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Angeliq is flagged as the suspect drug causing the adverse event.

Most Common Angeliq Adverse Events Reported to the FDA

What are the most common Angeliq adverse events reported to the FDA?

Metrorrhagia	28 (3.79%)
Vaginal Haemorrhage	27 (3.65%)
Hot Flush	26 (3.52%)
Headache	20 (2.71%)
Alopecia	17 (2.3%)
Syncope	15 (2.03%)
Vertigo	13 (1.76%)
Abdominal Pain	12 (1.62%)
Chills	11 (1.49%)
Hyperhidrosis	11 (1.49%)
Postmenopausal Haemorrhage	11 (1.49%)
	Show More
Anxiety	10 (1.35%)
Breast Pain	10 (1.35%)
Nausea	10 (1.35%)
Dyspnoea	9 (1.22%)
Pain In Extremity	9 (1.22%)
Weight Increased	9 (1.22%)
Breast Tenderness	8 (1.08%)
Dizziness	8 (1.08%)
Fatigue	8 (1.08%)
Nervousness	8 (1.08%)
Speech Disorder	8 (1.08%)
Asthenia	7 (.95%)
Vision Blurred	7 (.95%)
Aneurysm	6 (.81%)
Blood Pressure Fluctuation	6 (.81%)
Blood Pressure Increased	6 (.81%)
Breast Swelling	6 (.81%)
Depression	6 (.81%)
Muscle Spasms	6 (.81%)
No Adverse Event	6 (.81%)
Pruritus	6 (.81%)
Pyrexia	6 (.81%)
Endometrial Cancer Stage I	5 (.68%)
Hypersensitivity	5 (.68%)
Night Sweats	5 (.68%)
Vomiting	5 (.68%)
Weight Decreased	5 (.68%)
Abdominal Distension	4 (.54%)
Blood Pressure Diastolic Decreased	4 (.54%)
Drug Ineffective	4 (.54%)
Flatulence	4 (.54%)
Fluid Retention	4 (.54%)
Generalised Erythema	4 (.54%)
Genital Haemorrhage	4 (.54%)
Hypertensive Crisis	4 (.54%)
Laryngeal Oedema	4 (.54%)
Menorrhagia	4 (.54%)
Migraine	4 (.54%)
Pain	4 (.54%)
Urticaria	4 (.54%)
Abdominal Pain Upper	3 (.41%)
Back Pain	3 (.41%)
Blood Urine Present	3 (.41%)
Body Temperature Increased	3 (.41%)
Bronchospasm	3 (.41%)
Chest Discomfort	3 (.41%)
Chest Pain	3 (.41%)
Dysaesthesia	3 (.41%)
Eye Disorder	3 (.41%)
Eye Haemorrhage	3 (.41%)
Eye Inflammation	3 (.41%)
Face Oedema	3 (.41%)
Flushing	3 (.41%)
Hepatic Steatosis	3 (.41%)
Insomnia	3 (.41%)
Libido Decreased	3 (.41%)
Menopausal Symptoms	3 (.41%)
Mood Altered	3 (.41%)
Oedema Peripheral	3 (.41%)
Osteochondrosis	3 (.41%)
Palpitations	3 (.41%)
Paraesthesia	3 (.41%)
Photopsia	3 (.41%)
Polyuria	3 (.41%)
Tunnel Vision	3 (.41%)
Uterine Enlargement	3 (.41%)
Uterine Haemorrhage	3 (.41%)
Varicose Vein	3 (.41%)
Acne	2 (.27%)
Adnexa Uteri Pain	2 (.27%)
Alanine Aminotransferase Increased	2 (.27%)
Arteriovenous Fistula	2 (.27%)
Aspartate Aminotransferase Increase...	2 (.27%)
Blindness Unilateral	2 (.27%)
Blood Corticotrophin Increased	2 (.27%)
Blood Cortisol Increased	2 (.27%)
Blood Creatinine Increased	2 (.27%)
Blood Lactate Dehydrogenase Increas...	2 (.27%)
Blood Oestrogen Decreased	2 (.27%)
Breast Cancer Stage I	2 (.27%)
Breast Enlargement	2 (.27%)
Breast Mass	2 (.27%)
Cerebral Artery Embolism	2 (.27%)
Confusional State	2 (.27%)
Constipation	2 (.27%)
Cystitis	2 (.27%)
Decreased Appetite	2 (.27%)
Deep Vein Thrombosis	2 (.27%)
Diverticulitis	2 (.27%)
Drug Dose Omission	2 (.27%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Angeliq, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Angeliq is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Angeliq

What are the most common Angeliq adverse events reported to the FDA?

Neurological	43 (5.82%)
Menstrual Cycle And Uterine Bleedin...	39 (5.28%)
Gastrointestinal Signs	38 (5.14%)
Skin Appendage Conditions	37 (5.01%)
Breast	32 (4.33%)
Vascular	31 (4.19%)
Vulvovaginal Disorders	30 (4.06%)
Headaches	24 (3.25%)
Anxiety Disorders	20 (2.71%)
Epidermal And Dermal Conditions	18 (2.44%)
Respiratory	18 (2.44%)
	Show More
Physical Examination Topics	17 (2.3%)
Menopause And Related Conditions	15 (2.03%)
Vision	15 (2.03%)
Cardiac And Vascular Investigations	13 (1.76%)
Inner Ear And Viiith Cranial Nerve	13 (1.76%)
Musculoskeletal And Connective Tiss...	13 (1.76%)
Uterine, Pelvic And Broad Ligament	12 (1.62%)
Hepatic And Hepatobiliary	11 (1.49%)
Decreased And Nonspecific Blood Pre...	9 (1.22%)
Eye	8 (1.08%)
Medication Errors	8 (1.08%)
Therapeutic And Nontherapeutic Effe...	8 (1.08%)
Allergic Conditions	7 (.95%)
Depressed Mood Disorders	7 (.95%)
Endocrine Investigations	7 (.95%)
Infections - Pathogen Unspecified	7 (.95%)
Muscle	7 (.95%)
Aneurysms And Artery Dissections	6 (.81%)
Body Temperature Conditions	6 (.81%)
Hematology Investigations	6 (.81%)
Hepatobiliary	6 (.81%)
Oral Soft Tissue Conditions	6 (.81%)
Reproductive Tract	6 (.81%)
Upper Respiratory Tract Disorders	6 (.81%)
Ocular Infections, Irritations And ...	5 (.68%)
Renal And Urinary Tract Investigati...	5 (.68%)
Reproductive Neoplasms Female Malig...	5 (.68%)
Viral Infectious	5 (.68%)
Angiedema And Urticaria	4 (.54%)
Breast Neoplasms Malignant And Unsp...	4 (.54%)
Electrolyte And Fluid Balance Condi...	4 (.54%)
Vascular Hypertensive	4 (.54%)
Bronchial Disorders	3 (.41%)
Cardiac Disorder Signs	3 (.41%)
Fungal Infectious	3 (.41%)
Gastrointestinal Motility And Defec...	3 (.41%)
Mood Disorders	3 (.41%)
Movement Disorders	3 (.41%)
Neurological Disorders Of The Eye	3 (.41%)
Ocular Hemorrhages And Vascular	3 (.41%)
Retina, Choroid And Vitreous Hemorr...	3 (.41%)
Sexual Dysfunctions, Disturbances A...	3 (.41%)
Sleep Disorders	3 (.41%)
Tendon, Ligament And Cartilage	3 (.41%)
Urinary Tract Signs	3 (.41%)
Venous Varices	3 (.41%)
Appetite And General Nutritional	2 (.27%)
Cardiac Arrhythmias	2 (.27%)
Central Nervous System Vascular	2 (.27%)
Connective Tissue Disorders	2 (.27%)
Coronary Artery	2 (.27%)
Cranial Nerve Disorders	2 (.27%)
Deliria	2 (.27%)
Embolism And Thrombosis	2 (.27%)
Enzyme	2 (.27%)
Gastrointestinal Ulceration And Per...	2 (.27%)
Nervous System Neoplasms Malignant ...	2 (.27%)
Ovarian And Fallopian Tube	2 (.27%)
Product Quality Issues	2 (.27%)
Pulmonary Vascular	2 (.27%)
Renal Disorders	2 (.27%)
Salivary Gland Conditions	2 (.27%)
Suicidal And Self-injurious Behavio...	2 (.27%)
Breast Neoplasms Benign	1 (.14%)
Dental And Gingival Conditions	1 (.14%)
Diverticular	1 (.14%)
Endocrine Neoplasms Malignant And U...	1 (.14%)
Gastrointestinal Conditions	1 (.14%)
Hearing	1 (.14%)
Heart Failures	1 (.14%)
Injuries	1 (.14%)
Joint	1 (.14%)
Lifestyle Issues	1 (.14%)
Lower Respiratory Tract Disorders	1 (.14%)
Malabsorption Conditions	1 (.14%)
Mental Impairment	1 (.14%)
Mycobacterial Infectious	1 (.14%)
Nephropathies	1 (.14%)
Obstetric And Gynecological Therape...	1 (.14%)
Placental, Amniotic And Cavity Diso...	1 (.14%)
Pregnancy, Labour, Delivery And Pos...	1 (.14%)
Reproductive Neoplasms Female Benig...	1 (.14%)
Sleep Disturbances	1 (.14%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Angeliq, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Angeliq is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.